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and hemorrhagic complications after thrombolysis in stroke patients with and without AF.
Methods
Study Population
We used the Registry of the Canadian Stroke Network (RCSN) to identify patients admitted to 12 designated acute stroke centers in the province of Ontario, Canada between July 1, 2003 and June 30, 2008 . Patients with missing baseline characteristics (Canadian Neurological Scale score, glucose on admission, unique health identifier) (n=1005; 7.3%) were excluded. Further details on the RCSN can be obtained from the RCSN report at (http://www.rcsn. org).6,9 AF is one of the variables systematically collected in the RCSN. It includes participants with history of AF of any origin or documented on admission.
The iScore is a prognostic score that estimates functional outcomes in patients with an ischemic stroke early after hospitalization using clinical parameters and comorbid conditions (Supplemental Table 1 ). 6, 7 We calculated the iScore for each eligible participant in the RSCN. Details of the conceptualization of the iScore have been published elsewhere. 6 An online web-based tool (http://www.sorcan. ca/iscore) and iPhone version are currently available for practical use. Statistical Analysis χ 2 tests were used to compare categorical variables; ANOVA or Kruskal-Wallis tests were used to compare mean and median differences for continuous variables. We used terciles to determine whether a higher iScore was associated with poorer outcomes in patients with and without AF. As identified in a previous study on the response to thrombolysis, we used an iScore cutoff of 200 to compare favorable outcome (mRS 0-2) at discharge and risk of ICH. 8 Poisson regression models were used to estimate the relative risk (RR) of AF versus non-AF for the outcomes of interest with adjustment for variables in the iScore, hypertension, diabetes mellitus, hyperlipidemia, previous stroke or transient ischemic attack, dementia, myocardial infarction, smoking, level of consciousness on arrival, dysphasia, time from onset-to-treatment/admission, and arrival by ambulance. 10 We analyzed the interaction between the iScore and tPA in the whole cohort and in patients with and without AF.
Statistical analysis was performed using SAS version 9.2.2 (Cary, NC: SAS Institute Inc.). P values <0.05 were considered significant. Approvals from the St. Michael's Hospital review board and the RCSN Publications Committee were obtained.
Results
Among 12 686 patients with ischemic stroke in the RCSN sample, 2185 (17.2%) had AF. Patients with AF were more likely older, female, and had more severe strokes compared with non-AF patients. Other differences in baseline characteristics are summarized in Table 1 . The mean iScore was 35 points higher among AF compared with non-AF patients (mean iScore: 164. 4 [AF] versus 129.4 [non-AF]). Similar differences were observed for the scoring system to estimate 1-year mortality (Table 1) . AF during after the initial admission occurred in an additional 5.8% (611/10 501) patients with previously unrecognized AF.
Clinical Outcomes in Patients With AF
Overall, stroke patients with AF had higher short-and long-term mortality, and death or disability at discharge (Table 2 ). For example, there was a 2-fold higher risk of death at 30 days (RR, 2.19; 95% CI, 1.98-2.41) and at 1 year among stroke patients with AF compared with those without AF. Moreover, AF patients were less likely to be discharged home (RR, 0.88; 95% CI, 0.81-0.95) and had longer length of stay (14.4 days versus 12.6 days; P<0.001) compared with their non-AF counterparts.
Outcomes Stratified by the iScore Overall, for lower iScore values (terciles 1 and 2) there was no significant difference in death or disability at discharge, death at 30 days, and death at 1 year between patients with and without AF. Patients with AF with a higher iScore (tercile 3) had higher mortality at 30 days (RR, 1.23; 95% CI, 1.12-1.35) and at 1 year (RR, 1.18; 95% CI, 1.11-1.26) ( Table 2) . Stroke patients with AF were less likely discharged home compared with their non-AF counterparts in the terciles 2 and 3 strata.
Outcomes After Thrombolytic Therapy
Overall, 1689 (13.3%) patients received thrombolysis (1373 without AF and 316 with AF). Only 40 (2.4%) patients (10 in the non-tPA and 30 in the tPA group) received concomitant endovascular treatment.
After adjustment, thrombolysis was associated with a favorable outcome (mRS 0-2) in the whole cohort (RR, 1.15; 95% CI, 1.07-1.23) and for patients without AF (RR, 1.18; 95% CI, 1.10-1.27). No benefit was observed for patients with AF (RR, 0.91; 95% CI, 0.71-1.17).
There was no difference in the thrombolysis rate between AF (46.2%) and non-AF patients (53.8%) who had an iScore ≥200. Functional status at discharge in patients with and without AF stratified by tPA is summarized in Figure 1 . In the low iScore strata (iScore <200), AF patients had worse functional outcomes after tPA administration compared with non-AF patients (death or disability at discharge: 65.1% non-AF versus 80.9% AF; RR, 1.24; 95% CI, 1.16-1.35). No difference was observed between AF and non-AF patients in the high iScore strata (93.5% versus 93.8%). Similar results were observed after excluding patients who were dependent on admission (Supplemental Table 2 ). Table 3 ). Similar trends were observed for patients with symptomatic ICH (9.2% versus 6.4%; RR 1.43; 95% CI, 0.93-2.17). AF was not associated with higher risk of ICH (symptomatic or any type) after thrombolysis when stratified by the iScore (Table 3 ) likely attributable to the smaller sample sizes. Figure 2 represents the RR for a favorable outcome at each level of the iScore stratified by AF derived from the multivariable model in the whole cohort (n=12 686). There was an interaction between tPA and AF (P=0.0099) and between tPA and the iScore (P<0.0001) for a favorable outcome in the whole cohort (P<0.0001). In the stratified analysis by AF status, there was also an interaction between tPA and the iScore (P<0.0012) for a favorable outcome among patients without AF (Figure 2) . A similar trend was observed in the AF subgroup with a nonsignificant interaction (P=0.17) likely attributable to the smaller sample size. Together, these results suggest the iScore can predict the probability of a favorable outcome after thrombolysis in the entire cohort, but the benefit of tPA may decline more rapidly at lower iScore values among AF patients (iScore 125) compared with non-AF (iScore 165) (Figure 2A ).
Discussion
Patients with AF are at increased risk of stroke, 2 usually associated with poorer outcomes. 1 Particularly challenging is the prediction of a clinical response to thrombolysis considering the diverse interaction between AF with age and other coexisting comorbidities in stroke patients and the risk of hemorrhagic complications. 11, 12 In previous studies, our group showed the iScore, a validated prognostic score that includes AF, predicts clinical outcomes and response to thrombolysis. [6] [7] [8] In the present study, we showed an incremental mortality at 30 days and at 1 year and a lower probability of discharge home among patients with AF compared with patients without AF in the same high iScore strata. AF was associated with higher risk of death or disability and hemorrhagic complications after thrombolysis. The trend for a clinical response to tPA was similar between stroke patients with and without AF, and hence we believe that the lack of a significant interaction ( Figure 2D ) is likely attributable to the smaller sample size.
There are several tools available to predict clinical outcomes or response to thrombolysis. Interestingly, AF was not included in these scores. [13] [14] [15] [16] [17] Our results are consistent with previous observations showing poorer outcomes among patients with AF receiving thrombolysis. [18] [19] [20] [21] [22] Previous studies also found a higher risk of symptomatic ICH after tPA among patients with AF (odds ratio [OR], 2.95; 95% CI, 1.12-9.30). 18 We found an overall similar increased risk of ICH with a higher trend toward patients with higher iScore. Our study also showed that AF patients had higher iScore values (AF adds 10 points to the iScore, whereas AF patients had an average iScore 35 points greater than their non-AF counterparts). This is explained by the additional impact of older age, more severe strokes, and more comorbid conditions in patients with AF ( Table 1 ). The adverse impact of AF is likely attributable to larger areas of hypoperfusion and lower recanalization leading to larger infarct volumes and more severe hemorrhagic transformation. The differential response to thrombolysis in patients with AF has not been extensively studied. Most clinical trials were not powered to explore an interaction between AF and treatment effect. [25] [26] [27] [28] [29] In the NINDS tPA trial, AF (n=50) was associated with worse global outcome (OR, 0.57; 95% CI, 0.38-0.86), but there was no significant interaction with treatment. 28 In the European Cooperative Acute Stroke Study (ECASS) III trial, there were 53 patients with AF receiving tPA and 55 in the placebo arm. There was a trend for higher mortality and lower response to tPA among patients with AF. 29 In the recently published IST3 study, the authors reported no differential benefit when comparing tPA versus control among patients with (24.1% versus 22.3%) or without (42.2% versus 40.4%) AF. 30 In the VISTA Collaboration, among 3027 patients receiving thrombolysis, 1631 (53.9%) had a history of AF. 31 The authors found a similar magnitude of benefit with tPA compared with placebo for patients with AF (OR, 1.44; 95% CI, 1.12-1.73) and without AF (OR, 1.53; 95% CI, 1.39-1.69). Similar to our findings (Figure 1) , non-AF patients receiving tPA had a better favorable outcome (49.3% versus 33%; OR, 0.81; 95% CI, 0.66-1.00) if the mRS is categorized as 0 to 2 versus 3 to 6. There was no significant difference in ICH (asymptomatic or symptomatic) between AF and non-AF patients among tPA or controls. 31 In contrast to the VISTA results, we found a trend for a favorable outcome after tPA among AF patients, but not reaching significance, likely explained by the smaller tPA sample in our study.
In previous studies, we also demonstrated that the iScore improves on the accuracy of other simple models (only including age and stroke severity), which may underestimate poor clinical outcomes. 6 AF is highly prevalent and one of the top risk factors for poor functional outcomes (OR, 2.51; 95% CI, 2.17-2.91) after age and stroke severity. 6, 8 Moreover, the probability of achieving a favorable outcome is lower among patients with AF ( Figure 1 ) and sharply declined with higher iScore risk (Figure 2) .
Our study has several limitations and strengths. First, we were not able to evaluate imaging variables (eg, infarct size, recanalization) known to affect clinical outcomes. However, the intention of this study was to evaluate a differential effect of AF on outcomes when applying a clinical score. Second, a type II error may explain the observed trends (but not reaching significance) after tPA in AF patients. Third, the regression models to estimate a favorable outcome (Figure 2 ) may be unstable and should be viewed as hypothesis generating. Figure 2 . Adjusted probability of a favorable outcome (modified Rankin scale [mRS] 0-2) at discharge in tPA treated patients compared with non-tPA patients by the iScore. A, represents the probability of a favorable outcome in the whole population and patients with and without atrial fibrillation (AF). The probability of a favorable outcome and the 95% CI is represented for the whole population (B), for patients without AF (C), and for patients with AF (D). The horizontal line indicates the relative risk of 1 (no treatment effect). Dotted lines represent the 95% CI. See text for further details. by guest on October 31, 2017 http://stroke.ahajournals.org/ Downloaded from Strengths of our study include a large sample size comprising real world patients, a considerable number of individuals with AF and patients receiving tPA, and the use of a previously validated score with a nearly complete ascertainment of stroke severity and follow-up.
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This study suggests the iScore predicts outcomes both for patients with and without AF. Acute ischemic stroke patients with AF have higher mortality, poorer functional outcomes, greater risk of ICH, and a lower response to thrombolysis compared with non-AF stroke patients for a given high iScore. This is likely explained by the older age, more severe strokes, and higher prevalence of comorbidities as reflected by an average iScore 35 point higher in AF compared with non-AF patients. Nevertheless, thrombolysis may still be beneficial in AF individuals compared with not administering thrombolysis. The generally poor outcomes after ischemic stroke in patients with AF reinforces the major importance of therapies aimed at primary stroke prevention.
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